We need to move the debate on open clinical trial data forward

Few arguments can be made for withholding clinical trial data.1 One is an ethical issue over patient confidentiality; another is that disclosure leads to patient harm.

The drug industry understands the potential influence of academics, and rewards can be substantial. For example, according to Roche’s 2011 financial report, John Bell received 390 000 Swiss Francs (£260 450; €322 450; $420 000) last year for his role on the board of directors.2 What do Roche and its shareholders expect for this level of involvement and remuneration? And, how could this role facilitate …